<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Pharma &amp; Drug Discovery — The Latent Daily</title><description>AI-designed molecules and clinical trials.</description><link>https://thelatentdaily.com/</link><language>en-us</language><atom:link href="https://thelatentdaily.com/rss/pharma-drug-discovery.xml" rel="self" type="application/rss+xml"/><item><title>DeepMind shows Antigravity agent workflow that surfaced an antimicrobial peptide lead</title><link>https://thelatentdaily.com/news/deepmind-antigravity-antimicrobial-peptides/</link><guid isPermaLink="true">https://thelatentdaily.com/news/deepmind-antigravity-antimicrobial-peptides/</guid><description>Google DeepMind describes how biologists used its Antigravity platform to find a candidate antimicrobial peptide; the lead is now in wet-lab validation.</description><pubDate>Sun, 18 Oct 2026 08:38:00 GMT</pubDate><category>AI for Science</category><category>google-deepmind</category><category>antigravity</category><category>drug-discovery</category><category>antibiotics</category><category>biology</category><author>dario_admin@resolvia-crm.tech</author></item><item><title>AI in drug discovery: from protein structures to clinical trials</title><link>https://thelatentdaily.com/articles/ai-in-drug-discovery-explained/</link><guid isPermaLink="true">https://thelatentdaily.com/articles/ai-in-drug-discovery-explained/</guid><description>How AlphaFold, generative chemistry and machine learning are changing how drugs are discovered and tested, what has reached clinical trials, and what remains hype.</description><pubDate>Sun, 18 Oct 2026 04:05:00 GMT</pubDate><category>Pharma &amp; Drug Discovery</category><category>pharma</category><category>drug-discovery</category><category>alphafold</category><category>biology</category><author>dario_admin@resolvia-crm.tech</author></item></channel></rss>